BioVie Inc(BIVI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BIVI BioVie Inc

Pre-Mkt 09-28 06:23:04 EDT

1.61

+0.00

-0.31%

盘前1.69

+0.09+5.43%

05:50 EDT

High1.75	Low1.58	Vol458.95K
Open1.66	D1 Closing1.61	Amplitude10.56%
Mkt Cap13.56M	Tradable Cap13.50M	Total Shares8.45M
T/O759.06K	T/O Rate5.46%	Tradable Shares8.41M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BIVI","market":"US","secType":"STK","nameCN":"BioVie Inc","latestPrice":1.605,"timestamp":1790366400000,"preClose":1.61,"halted":0,"volume":458952,"hourTrading":{"tag":"盘前","latestPrice":1.6921,"preClose":1.605,"latestTime":"05:50 EDT","volume":238,"amount":381.13850740000004,"timestamp":1790589046152,"change":0.0871,"changeRate":0.054268,"amplitude":0.057383},"delay":0,"changeRate":-0.0031055900621118726,"floatShares":8409800,"shares":8451148,"eps":-3.049999,"marketStatus":"Pre-Mkt","change":-0.005,"latestTime":"09-28 06:23:04 EDT","open":1.66,"high":1.75,"low":1.58,"amount":759055.4807472,"amplitude":0.10559,"askPrice":1.83,"askSize":100,"bidPrice":1.47,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-3.049999,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1790602200000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":1.605,"preHourTrading":{"tag":"盘前","latestPrice":1.6921,"preClose":1.605,"latestTime":"05:50 EDT","volume":238,"amount":381.13850740000004,"timestamp":1790589046152,"change":0.0871,"changeRate":0.054268,"amplitude":0.057383},"postHourTrading":{"tag":"盘后","latestPrice":1.59,"preClose":1.605,"latestTime":"19:30 EDT","volume":757,"amount":1203.8,"timestamp":1790379004049,"change":-0.015,"changeRate":-0.009346,"amplitude":0.017508},"volumeRatio":1.5586405604315177,"impliedVol":1.6378,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/BIVI","defaultTab":"news","newsList":[{"id":"2667862671","title":"U.S. Stocks on the MOVE-Forgent Power, Vera Bradley, Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2667862671","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667862671?lang=en_us&edition=fundamental","pubTime":"2026-09-16 00:53","pubTimestamp":1789491227,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Forgent Power, Vera Bradley, Wells FargoSeptember 15 (Reuters)-Wall Street's main indexes slipped on Tuesday, dragged down by higher crude prices, elevated Treasury yields","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260915:nL6N457105:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PJP","PLAY","LEGN","HRTS","CANC","RIVN","WAY","07711","LLY","COIN","GDOC","HUT","IYF","OTIS","CONL","WFC","CNTB","RIOT","IHE","CRPT","KBWB","LFGY","ICOI","TRUH","MRAL","IMRA","PDM","THNR","09711","BIVI","DAPP","XLV","COII","MARA","09311","VERA","LLYZ","PEJ","SYY","AXON","RVNL","MEMS","WGMI","COIO","VRA","OWNB","RXL","BITQ","FPS","LLII"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667642226","title":"BioVie Falls After Long COVID Drug Fails to Show Benefit in Overall Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2667642226","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667642226?lang=en_us&edition=fundamental","pubTime":"2026-09-15 20:33","pubTimestamp":1789475616,"startTime":"0","endTime":"0","summary":"BUZZ-BioVie falls after long COVID drug fails to show benefit in overall trial** Shares of drug developer BioVieBIVI.Ofall 10.7% to $1.83 premarket** Company says its experimental oral drug bezisterim did not reach statistical significance on any of the 22 measures in a mid-stage trial that enrolled 203 patients with long COVID** Long COVID can cause symptoms that persist after the initial COVID-19 infection, including fatigue, difficulty thinking, sleep problems and worsening symptoms after physical or mental activity** Results on 21 measures favored the drug, but significant benefits were limited to pre-specified groups with more severe fatigue, thinking problems or worsening symptoms after activity - BIVI** Patients in these groups accounted for about 78% of trial participants; company says subgroup findings were exploratory and need confirmation in a larger late-stage trial** Safety was similar to placebo, with no serious side effects reported among patients receiving bezisterim** ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260915:nL4N4570UZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIVI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667644310","title":"BioVie announces topline results from ADDRESS-LC trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2667644310","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667644310?lang=en_us&edition=fundamental","pubTime":"2026-09-15 19:40","pubTimestamp":1789472425,"startTime":"0","endTime":"0","summary":"BioVie (BIVI) announced topline results from the company’s Phase 2 ADDRESS-LC trial evaluating its investigational drug candidate bezisterim, an or...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/biovie-announces-topline-results-from-address-lc-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/biovie-announces-topline-results-from-address-lc-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BIVI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667737641","title":"BioVie Announces Topline Results from Phase 2 Address‑Lc Trial Evaluating Bezisterim for the Treatment of Neurological Symptoms Associated with Long Covid","url":"https://stock-news.laohu8.com/highlight/detail?id=2667737641","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667737641?lang=en_us&edition=fundamental","pubTime":"2026-09-15 19:30","pubTimestamp":1789471800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260915:nTUA71ZLNJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BIVI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667641760","title":"BioVie - 41.6% of Bezisterim Patients Experienced Adverse Events vs 55.9% for Placebo","url":"https://stock-news.laohu8.com/highlight/detail?id=2667641760","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667641760?lang=en_us&edition=fundamental","pubTime":"2026-09-15 19:30","pubTimestamp":1789471800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260915:nTUA71ZLNJ:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BIVI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667641754","title":"BioVie - Bezisterim Safety and Tolerability Profile Similar to Placebo","url":"https://stock-news.laohu8.com/highlight/detail?id=2667641754","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667641754?lang=en_us&edition=fundamental","pubTime":"2026-09-15 19:30","pubTimestamp":1789471800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260915:nTUA71ZLNJ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BIVI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667064173","title":"BioVie - Bezisterim Shows Advantage over Placebo on 21 of 22 Endpoints in Phase 2 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2667064173","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667064173?lang=en_us&edition=fundamental","pubTime":"2026-09-15 19:30","pubTimestamp":1789471800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260915:nTUA71ZLNJ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BIVI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667641428","title":"NASDAQ Trade Halt Halt News Pending at 07:25 Am","url":"https://stock-news.laohu8.com/highlight/detail?id=2667641428","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667641428?lang=en_us&edition=fundamental","pubTime":"2026-09-15 19:25","pubTimestamp":1789471500,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALTHALT NEWS PENDING AT 07:25 AM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260915:nAQN2MJ9GJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIVI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667261696","title":"BioVie to Host Conference Call to Discuss Topline Data from Phase 2 ADDRESS-LC Trial and the Potential of Bezisterim in Long Covid","url":"https://stock-news.laohu8.com/highlight/detail?id=2667261696","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667261696?lang=en_us&edition=fundamental","pubTime":"2026-09-15 04:01","pubTimestamp":1789416060,"startTime":"0","endTime":"0","summary":"Conference call scheduled for Tuesday, September 15, 2026, at 8:30 a.m. Eastern Time (ET)CARSON CITY, Nev., Sept.  14, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (\"BioVie\" or the \"Company\"), ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/14/3361532/0/en/biovie-to-host-conference-call-to-discuss-topline-data-from-phase-2-address-lc-trial-and-the-potential-of-bezisterim-in-long-covid.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENFR","LU1169589451.USD","AD","BK4132","USAI","UMI","LU1169590202.USD","AMZA","EMLP","BK4023","BK4139","BK4588","ET","BK4561","EIPX","AMLP","BK4581","TNGY","TPZ","PD","BK4590","MDST","BK4585","BK4144","MLPA","EIPI","BIVI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667657864","title":"BioVie Signs At-the-Market Equity Sales Agreement for up to $6.46 Million Class a Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2667657864","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667657864?lang=en_us&edition=fundamental","pubTime":"2026-09-14 18:02","pubTimestamp":1789380161,"startTime":"0","endTime":"0","summary":"BioVie signs at-the-market equity sales agreement for up to $6.46 million Class A sharesBioVie entered an at-the-market sales agreement with A.G.P./Alliance Global Partners to sell up to $6.46 million","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nNDL72GLfQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIVI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667652042","title":"BioVie Inc Files for Atm Offering of up to About $6.5 Mln Common Stock - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2667652042","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667652042?lang=en_us&edition=fundamental","pubTime":"2026-09-14 18:02","pubTimestamp":1789380149,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nFWN45603P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BIVI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666531055","title":"Biovica Q1 FY27 Operating Loss Widens to SEK 20.33 Million; Net Sales Rise 56% to SEK 4.04 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2666531055","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666531055?lang=en_us&edition=fundamental","pubTime":"2026-09-10 00:17","pubTimestamp":1788970655,"startTime":"0","endTime":"0","summary":"Biovica Q1 FY27 operating loss widens to SEK 20.33 million; net sales rise 56% to SEK 4.04 millionBiovica posted Q1 net sales of SEK 4.04 million, up 56% year over year, driven by continued strong mom","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nNDL6F13q6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BIVI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665327608","title":"BioVie Seeks FDA End-of-Phase 2 Meeting to Advance Bezisterim Phase 3 Parkinson’s Trial Design","url":"https://stock-news.laohu8.com/highlight/detail?id=2665327608","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665327608?lang=en_us&edition=fundamental","pubTime":"2026-09-08 19:31","pubTimestamp":1788867097,"startTime":"0","endTime":"0","summary":"BioVie seeks FDA end-of-Phase 2 meeting to advance bezisterim Phase 3 Parkinson’s trial designBioVie opened the next stage of FDA engagement to advance a Phase 3 program for bezisterim in Parkinson’s ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDL6dvTkh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","SG9999014021.USD","BK4112","IE00BQXX3D17.EUR","BK4139","IE00BQXX3F31.USD","LU2095319765.USD","NDAQ","BK4588","IE00B64PRP62.GBP","LU0314104364.USD","LU2210149790.SGD","SG9999014013.SGD","IE00BGHQF748.EUR","IE00BN0W2W23.USD","IE00BQXX3C00.GBP","IE00BN0W2V16.EUR","LU2210150020.SGD","BK4585","IE00BKPKM429.USD","IE00B3QW5Z07.USD","BIVI","SG9999014005.SGD","IE00BN0W2T93.GBP","BCDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665432757","title":"BioVie Announces Update to Parkinson’s Phase 3 Development Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2665432757","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665432757?lang=en_us&edition=fundamental","pubTime":"2026-09-08 19:30","pubTimestamp":1788867001,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nTUABTQ932:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BIVI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665276493","title":"BioVie - Requests End-of-Phase 2 Meeting with FDA, Expects Feedback Before Year-End","url":"https://stock-news.laohu8.com/highlight/detail?id=2665276493","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665276493?lang=en_us&edition=fundamental","pubTime":"2026-09-08 19:30","pubTimestamp":1788867001,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nTUABTQ932:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BIVI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663008114","title":"BioVie Completes Treatment Phase of Phase 2 Long COVID Trial for Bezisterim","url":"https://stock-news.laohu8.com/highlight/detail?id=2663008114","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663008114?lang=en_us&edition=fundamental","pubTime":"2026-08-31 20:05","pubTimestamp":1788177947,"startTime":"0","endTime":"0","summary":"BioVie completes treatment phase of Phase 2 Long COVID trial for bezisterimBioVie completed the treatment phase of its Phase 2 ADDRESS-LC trial of bezisterim for neurological Long COVID symptoms.Topli","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nNDL16GfyF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","SG9999014005.SGD","BCDF","IE00BN0W2W23.USD","IE00BQXX3F31.USD","BK4588","BK4112","IE00BGHQF748.EUR","IE00BN0W2V16.EUR","LU0314104364.USD","IE00B64PRP62.GBP","LU2210149790.SGD","SG9999014021.USD","BIVI","SG9999014039.USD","BK4585","LU2095319765.USD","IE00BQXX3D17.EUR","SG9999014013.SGD","IE00BQXX3C00.GBP","BK4139","IE00BKPKM429.USD","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663008643","title":"BioVie - Topline Results for Address-Lc Expected Before End of September 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2663008643","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663008643?lang=en_us&edition=fundamental","pubTime":"2026-08-31 20:00","pubTimestamp":1788177602,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nTUA6QMMVV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BIVI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663008528","title":"BioVie Announces Completion of Treatment Phase of Address-Lc Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long Covid","url":"https://stock-news.laohu8.com/highlight/detail?id=2663008528","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663008528?lang=en_us&edition=fundamental","pubTime":"2026-08-31 20:00","pubTimestamp":1788177602,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nTUA6QMMVV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BIVI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663197350","title":"BioVie President and CEO Cuong V Do Acquires 15,210 Shares Worth $31,637.68","url":"https://stock-news.laohu8.com/highlight/detail?id=2663197350","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663197350?lang=en_us&edition=fundamental","pubTime":"2026-08-29 08:58","pubTimestamp":1787965103,"startTime":"0","endTime":"0","summary":"BioVie President and CEO Cuong V Do acquires 15,210 shares worth $31,637.68BioVie President and CEO Cuong V Do bought 15,210 common shares in open-market purchases at a weighted-average price of $2.08","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260829:nNDL3FTc7l:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"BioVie President and CEO Cuong V Do Acquires 15,210 Shares Worth $31,637.68","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BIVI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660444713","title":"Top Premarket Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2660444713","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660444713?lang=en_us&edition=fundamental","pubTime":"2026-08-19 19:11","pubTimestamp":1787137912,"startTime":"0","endTime":"0","summary":"Rising Dragon Acquisition  shares were up more than 198% in Wednesday's premarket activity following a 0.7% gain in the previous session.Tenon Medical  stock was up 85% after closing 11% higher at Tuesday's close.Zeta Network Group  shares were up 63% following a 5.2% increase at Tuesday's close.BioVie  stock was 57% higher, recovering from the previous session's 18% loss.FreeCast  shares were up 25% following a 144% rise on Tuesday when the company said it acquired full control of Investor News Channel and plans to relaunch it as a 24/7 global Free Ad-Supported Streaming Television network slated for November.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RDAC","BIVI","BK4082","BK4108","TNON","BK4204","ZNB","BK4139","CAST"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.bioviepharma.com","stockEarnings":[{"period":"1week","weight":-0.0031},{"period":"1month","weight":-0.2393},{"period":"3month","weight":-0.1727},{"period":"6month","weight":0.1801},{"period":"1year","weight":-0.1083},{"period":"ytd","weight":0.3836}],"compareEarnings":[{"period":"1week","weight":0.0127},{"period":"1month","weight":0.0069},{"period":"3month","weight":0.0581},{"period":"6month","weight":0.2165},{"period":"1year","weight":0.1722},{"period":"ytd","weight":0.1311}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.005325},{"month":2,"riseRate":0.5,"avgChangeRate":0.259645},{"month":3,"riseRate":0.625,"avgChangeRate":-0.036628},{"month":4,"riseRate":0.375,"avgChangeRate":0.025089},{"month":5,"riseRate":0.222222,"avgChangeRate":-0.110348},{"month":6,"riseRate":0.555556,"avgChangeRate":0.426902},{"month":7,"riseRate":0.444444,"avgChangeRate":0.260814},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.130957},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.177424},{"month":10,"riseRate":0.375,"avgChangeRate":0.201324},{"month":11,"riseRate":0.5,"avgChangeRate":-0.005666},{"month":12,"riseRate":0.25,"avgChangeRate":-0.131533}],"exchange":"NASDAQ","name":"BioVie Inc","nameEN":"BioVie Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BioVie Inc(BIVI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest BioVie Inc(BIVI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"BioVie Inc,BIVI,BioVie Inc股票,BioVie Inc股票老虎,BioVie Inc股票老虎国际,BioVie Inc行情,BioVie Inc股票行情,BioVie Inc股价,BioVie Inc股市,BioVie Inc股票价格,BioVie Inc股票交易,BioVie Inc股票购买,BioVie Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BioVie Inc(BIVI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest BioVie Inc(BIVI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}